Coherus BioSciences Inc. - Rasio nilai perusahaan marang dodolan CHRS

Simbol resmi perusahaan coherus.com (CHRS)

Coherus Biosciences' transition toward developing unique oncology drugs opens growth opportunities, which is reflected in the EV/Revenue ratio from GURU.Markets via the 852.91 metric, capturing this status. Stable demand for cancer therapy provides the business with macro resilience. However, cash flow volatility and pricing pressure in the US create certain challenges for the predictability of final earnings.

Coherus (CHRS): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Coherus BioSciences, Inc. - rincian analitis lan metrik utama (CHRS)

- rega lan prakiraan konsensus rega:
- data saldo dhuwit lan arus kas:
Pambiji fundamental perusahaan:CHRS, Coherus Biosciences
Produk sing diprodhuksi Coherus BioSciences

Institutional capital utilizes this metric to determine the fair market value of Coherus Biosciences (CHRS). The calculation combines market capitalization and net debt, comparing the resulting sum to annual sales volume. The price-to-sales ratio trend reflects the degree of business overvaluation relative to actual cash flows. Effective commercialization of drugs by the industry's top experts should maintain a stable trend for this indicator. Low values confirm the fundamental resilience of the asset.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan HRTX (Heron Therapeutics Inc)|Nuvectis - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CRBP (Corbus Pharma)|CRDF: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan beyondspringpharma.com (BYSI)|Rasio nilai perusahaan marang pendapatan bioatla.com|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales